Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Recent medical news supports the reasoning behind the innovative Wellness Incentive Program offered by Teachers Health Trust ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

The report was based on Google search patterns in 2024 and has identified five key shifts shaping the health and wellness ...